Author:
Okoh Emeka E.,Ojule Inumanye N.,Amah Linda O.,Okoh Joel C.,Sibeudu Nnaemeka E.,Odumegwu Stella I.
Abstract
Background: Lepra reactions occur among patients treated for leprosy. This study aimed to assess the pattern and predictors of lepra reactions in southeast Nigeria.
Methods: This is a convergent parallel mixed-methods study that determined the pattern and explored the experiences of leprosy patients. Participants were recruited by cluster sampling technique. Chi-square test and binary logistic regression analysis were done. In addition, in-depth and key informant interviews were conducted.
Results: There were 71 participants in total, comprising 35 males (49.3%) and 36 females (50.7%) with a mean age of 60.39±16.327. The prevalence of type 1 and type 2 lepra reactions were 59.2% (95% CI 47.14-70.17) and 35.2% (95% CI 27.30-50.07) respectively. Type 1 lepra reaction (LR) was significantly associated with gender (p<0.023) and farming (p<0.044). Furthermore, Paucibacillary leprosy (PB) was significantly associated with both types 1 (p<0.022) and 2 (p<0.011) lepra reactions. Type of diagnosis (PB) was a significant predictor of type 1 LR 5.89 (95% CI 1.58 - 21.99) and type 2 LR 8.76 (95% CI 1.67-46.15). Worsening and new lesions led to discrimination and stigmatization for leprosy survivors.
Conclusions: Lepra reactions are common among leprosy patients in southeast Nigeria. Male gender, farming and PB leprosy were found to be predictors of leprosy reactions.
Reference40 articles.
1. World Health Organization. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. InEnding the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021–2030 2020.
2. Santé O. World Health Organization. Global leprosy update, 2017: reducing the disease burden due to leprosy–situation de la lèpre dans le monde, 2017: reduction de la charge de morbidité due à la lèpre. Wkly. Epidemiol Rec. 2018:445-56.
3. Scollard D, Joyce MP, Gillis TP. Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases. Clinical Infectious Diseases. 2006;43(2):19-22.
4. Motta ACF, Pereira KJ, Tarquínio DC, Vieira MB, Miyake K, Foss NT. Leprosy reactions: Coinfections as a possible risk factor. Clinics. 2012;67(10):1145-8.
5. Nery C, Machado AM, Bernardes Filho F, Oliveira SC, Quintanilha J, Sales AM. Compreender melhor o estado reacional tipo 1 para o diagnóstico e tratamento precoces: Uma forma de se evitar as incapacidades na hanseníase. An Bras Dermatol. 2013;88(5):787-92.